Li J, et al. - In diabetic patients from four US health systems making up the Chronic Hepatitis Cohort Study (CHeCS), researchers studied whether the risk of acute coronary syndrome, end-stage renal disease, ischemic stroke, and retinopathy was influenced by antiviral treatment for hepatitis C (HCV). For this investigation, CHeCS HCV patients with diagnosis codes for type 2 diabetes who were on antidiabetic medications were included. Irrespective of cirrhosis, effective HCV treatment in patients with type 2 diabetes significantly lowered the incidence of acute coronary syndrome, end-stage renal disease, ischemic stroke, and retinopathy. The importance of HCV antiviral therapy among patients with type 2 diabetes to reduce the risk of these extrahepatic outcomes was supported in this investigation.